Centessa Acquisition Deal Hinges on FDA Approval: The Real Game Begins
On June 24, Eli Lilly completed its acquisition of Centessa Pharmaceuticals, paying $38 in cash per ordinary share plus non-transferable Contingent Value Rights (CVRs) that could deliver up to an additional $9 per share depending on future U.S. Food and Drug Administration (FDA) approvals. Following the closing, Parallon Capital Management confirmed in its amended Schedule 13D/A filed June 26 that it has divested its entire equity stake and holds no further shares.
The CVR structure is three-tiered: if Centessa’s orexin-2 receptor agonists—cleminorexton (formerly ORX750) or ORX142—secure FDA approval for narcolepsy type 2 and idiopathic hypersomnia within specified timeframes, holders will receive $2 and $5 per share, respectively. An additional $2 per share becomes payable if either therapy achieves its first FDA approval for any indication on or before January 1, 2030.
Headquartered in Cheshire, U.K., Centessa is a clinical-stage biotech developing oral OX2R-targeted therapies for sleep-wake disorders and neuropsychiatric conditions. Its lead candidate, cleminorexton, showed significant improvements in wakefulness and daytime sleepiness in a Phase 2a trial involving narcolepsy types 1 and 2 and idiopathic hypersomnia, paving the way for late-stage studies and regulatory submissions. Centessa’s other programs, ORX142 and ORX489, aim to expand into neurological, neurodegenerative and psychiatric indications. Through this acquisition, Lilly bolsters its orexin portfolio across sleep medicine and neuroscience.
Recent corporate milestones cleared the path swiftly. On June 12, Centessa shareholders approved the Scheme of Arrangement with Lilly, and on June 22 the U.K. High Court sanctioned the merger. Effective June 24, Nasdaq suspended trading of Centessa ADSs and the company filed Forms 25 and 15 to delist and deregister its securities. In an 8-K on the same day, Centessa repaid and terminated its Oxford Finance loan facility, simplifying its balance sheet. Early investors—including Medicxi and Index Ventures—filed SEC Form 4s exchanging their shares for $38 in cash plus CVRs, completing their exits. Of the roughly $7.8 billion total deal value, $6.3 billion is fixed consideration, while the remaining $1.5 billion in CVRs hinges on FDA approval outcomes, making regulatory milestones the principal drivers of future investor returns.